Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
**Description:** 2-(2-qunolin‑3‑ylpyridin‑4‑yl)‑1,5,6,7-tetrahydro‑4H-pyrrolo[3,2-c]pyridin‑4-one is a synthetic small molecule belonging to the pyrrolopyridine class. It has been studied as an experimental compound and is not approved for clinical use. The primary mechanism of action identified for this molecule is inhibition of MAP kinase–activated protein kinase 5 (MAPKAPK5) and MAP kinase–activated protein kinase 2 (MAPKAPK2), both of which are serine/threonine kinases involved in cellular stress response pathways. By inhibiting these kinases it may modulate inflammatory or stress-related signaling cascades; however its clinical applications remain unestablished and no indications or trials have been reported in humans.[1][9]
- Other names
- 2-[2-(quinolin-3-yl)pyridin-4-yl]-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one
02
Targets
MK2 (Mitogen-activated protein kinase-activated protein kinase 2)MAPKAPK3 (MAP kinase-activated protein kinase 3)MAPKAPK5 (Mitogen-activated protein kinase–activated protein kinase 5)
Beyond the preview
Go deeper on 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2-(2-quinolin-3-ylpyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one.